Article Text

Download PDFPDF
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial
  1. Michael Weinblatt1,
  2. Michael Schiff2,
  3. Allan Goldman3,
  4. Joel Kremer4,
  5. Michael Luggen5,
  6. Tracy Li6,
  7. Dalei Chen6,
  8. Jean-Claude Becker6
  1. 1Brigham and Women’s Hospital, Boston, Massachusetts, USA
  2. 2Denver Arthritis Clinic, Denver, Colorado, USA
  3. 3Milwaukee Rheumatology Center, Milwaukee, Wisconsin, USA
  4. 4Albany Medical College, Albany, New York, USA
  5. 5University of Cincinnati Medical Center, Cincinnati, Ohio, USA
  6. 6Bristol-Myers Squibb, Princeton, New Jersey, USA
  1. Correspondence to:
    Dr Michael Weinblatt
    Rheumatology & Immunology, Brigham & Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA; mweinblatt{at}


Objective: To investigate the efficacy and safety of abatacept in combination with etanercept in patients with active rheumatoid arthritis during a 1-year, randomised, placebo-controlled, double-blind phase, followed by an open-label, long-term extension (LTE).

Methods: Patients continued etanercept (25 mg twice weekly) and were randomised to receive abatacept 2 mg/kg (n = 85) or placebo (n = 36). As the effective dose of abatacept was established as 10 mg/kg in a separate trial, all patients received abatacept 10 mg/kg and etanercept during the LTE.

Results: A total of 121 patients were randomised; 80 completed double-blind treatment and entered the LTE. During double-blind treatment, the difference in the percentage of patients achieving the primary end point (modified American College of Rheumatology (ACR) 20 response at 6 months) was not significant between groups (48.2% v 30.6%; p = 0.072). At 1 year, no notable changes in modified ACR responses were observed. Subsequent to the dosing change, similar modified ACR responses were seen during the LTE. Significant improvements in quality of life were observed with abatacept and etanercept versus placebo and etanercept in five of the eight short-form 36 subscales at 1 year. More abatacept and etanercept-treated patients experienced serious adverse events (SAEs) at 1 year than patients receiving placebo and etanercept (16.5% v 2.8%), with 3.5% v 0% experiencing serious infections.

Conclusion: The combination of abatacept (at a dose of 2 mg/kg during the double-blind phase and 10 mg/kg during the LTE) and etanercept was associated with an increase in SAEs, including serious infections, with limited clinical effect. On the basis of the limited efficacy findings and safety concerns, abatacept in combination with etanercept should not be used for rheumatoid arthritis treatment.

  • ACR, American College of Rheumatology
  • CRP, C reactive protein
  • DMARD, disease-modifying antirheumatic drug
  • LTE, long-term extension
  • MCS, mental component summary
  • MTX, methotrexate
  • PCS, physical component summary
  • SAE, serious adverse event
  • SF-36, short-form 36

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.